guest ::
| Home > Publications database > Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference. > print |
| Home > Publications database > Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference. > print |
| 001 | 296013 | ||
| 005 | 20250819094613.0 | ||
| 024 | 7 | _ | |a 10.1080/2162402X.2024.2432726 |2 doi |
| 024 | 7 | _ | |a pmid:39696783 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC11660406 |2 pmc |
| 024 | 7 | _ | |a 2162-4011 |2 ISSN |
| 024 | 7 | _ | |a 2162-402X |2 ISSN |
| 037 | _ | _ | |a DKFZ-2024-02756 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Laurent, Pierre-Antoine |b 0 |
| 245 | _ | _ | |a Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference. |
| 260 | _ | _ | |a Abingdon |c 2025 |b Taylor & Franics |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1755589552_6400 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Over the last decade, the annual Immunorad Conference, held under the joint auspicies of Gustave Roussy (Villejuif, France) and the Weill Cornell Medical College (New-York, USA) has aimed at exploring the latest advancements in the fields of tumor immunology and radiotherapy-immunotherapy combinations for the treatment of cancer. Gathering medical oncologists, radiation oncologists, physicians and researchers with esteemed expertise in these fields, the Immunorad Conference bridges the gap between preclinical outcomes and clinical opportunities. Thus, it paves a promising way toward optimizing radiotherapy-immunotherapy combinations and, from a broader perspective, improving therapeutic strategies for patients with cancer. Herein, we report on the topics developed by key-opinion leaders during the 7th Immunorad Conference held in Paris-Les Cordeliers (France) from September 27th to 29th 2023, and set the stage for the 8th edition of Immunorad which will be held at Weill Cornell Medical College (New-York, USA) in October 2024. |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Cancer |2 Other |
| 650 | _ | 7 | |a FLASH radiotherapy |2 Other |
| 650 | _ | 7 | |a T cells |2 Other |
| 650 | _ | 7 | |a immune checkpoint |2 Other |
| 650 | _ | 7 | |a immunorad |2 Other |
| 650 | _ | 7 | |a immunotherapy |2 Other |
| 650 | _ | 7 | |a low-dose radiotherapy |2 Other |
| 650 | _ | 7 | |a lymph-node sparing |2 Other |
| 650 | _ | 7 | |a radiotherapy |2 Other |
| 650 | _ | 7 | |a tumor-associated macrophages |2 Other |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Neoplasms: immunology |2 MeSH |
| 650 | _ | 2 | |a Neoplasms: radiotherapy |2 MeSH |
| 650 | _ | 2 | |a Neoplasms: therapy |2 MeSH |
| 650 | _ | 2 | |a Immunotherapy: methods |2 MeSH |
| 650 | _ | 2 | |a Combined Modality Therapy |2 MeSH |
| 650 | _ | 2 | |a Radiotherapy: methods |2 MeSH |
| 700 | 1 | _ | |a André, Fabrice |b 1 |
| 700 | 1 | _ | |a Bobard, Alexandre |b 2 |
| 700 | 1 | _ | |a Deandreis, Desiree |b 3 |
| 700 | 1 | _ | |a Demaria, Sandra |b 4 |
| 700 | 1 | _ | |a Depil, Stephane |b 5 |
| 700 | 1 | _ | |a Eichmüller, Stefan |0 P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944 |b 6 |u dkfz |
| 700 | 1 | _ | |a Fernandez-Palomo, Cristian |b 7 |
| 700 | 1 | _ | |a Foijer, Floris |b 8 |
| 700 | 1 | _ | |a Galluzzi, Lorenzo |b 9 |
| 700 | 1 | _ | |a Galon, Jérôme |b 10 |
| 700 | 1 | _ | |a Guckenberger, Matthias |b 11 |
| 700 | 1 | _ | |a Harrington, Kevin J |b 12 |
| 700 | 1 | _ | |a Herrera, Fernanda G |b 13 |
| 700 | 1 | _ | |a Huber, Peter |0 P:(DE-He78)3291aaac20f3d603d96744c1f0890028 |b 14 |u dkfz |
| 700 | 1 | _ | |a Italiano, Antoine |b 15 |
| 700 | 1 | _ | |a Karam, Sana D |b 16 |
| 700 | 1 | _ | |a Kroemer, Guido |b 17 |
| 700 | 1 | _ | |a Lambin, Philippe |0 0000-0001-7961-0191 |b 18 |
| 700 | 1 | _ | |a Leuschner, Carola |b 19 |
| 700 | 1 | _ | |a Mantovani, Alberto |b 20 |
| 700 | 1 | _ | |a Meylan, Etienne |b 21 |
| 700 | 1 | _ | |a Mondini, Michele |0 0000-0001-5803-0083 |b 22 |
| 700 | 1 | _ | |a Pittet, Mikael J |b 23 |
| 700 | 1 | _ | |a Pouget, Jean-Pierre |b 24 |
| 700 | 1 | _ | |a Remon, Jordi |b 25 |
| 700 | 1 | _ | |a Sørensen, Claus S |b 26 |
| 700 | 1 | _ | |a Sotiriou, Christos |b 27 |
| 700 | 1 | _ | |a Vanpouille-Box, Claire |b 28 |
| 700 | 1 | _ | |a Weichselbaum, Ralph R |b 29 |
| 700 | 1 | _ | |a Welsh, James W |b 30 |
| 700 | 1 | _ | |a Zitvogel, Laurence |b 31 |
| 700 | 1 | _ | |a Formenti, Silvia C |b 32 |
| 700 | 1 | _ | |a Deutsch, Eric |0 0000-0002-8223-3697 |b 33 |
| 773 | _ | _ | |a 10.1080/2162402X.2024.2432726 |g Vol. 14, no. 1, p. 2432726 |0 PERI:(DE-600)2645309-5 |n 1 |p 2432726 |t OncoImmunology |v 14 |y 2025 |x 2162-4011 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:296013 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 14 |6 P:(DE-He78)3291aaac20f3d603d96744c1f0890028 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ONCOIMMUNOLOGY : 2022 |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2022-11-18T12:16:37Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2022-11-18T12:16:37Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2022-11-18T12:16:37Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-08-19 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-08-19 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-08-19 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b ONCOIMMUNOLOGY : 2022 |d 2023-08-19 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2023-08-19 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2023-08-19 |
| 920 | 1 | _ | |0 I:(DE-He78)D210-20160331 |k D210 |l GMP-Einheit Zelluläre Therapie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)E055-20160331 |k E055 |l E055 KKE Molekulare Radioonkologie |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)D210-20160331 |
| 980 | _ | _ | |a I:(DE-He78)E055-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|